Genmab and Seagen reach primary endpoints in Phase III cervical cancer study

The results expand on previous results from earlier trials.
Genmab har sammen med partneren Seagen med lægemidlet Tikdav nået de primære endemål i et fase 3-studie af andenlinje-behandling af patienter med tilbagevendende eller metastatisk livmoderhalskræft. | Photo: Medwatch
Genmab har sammen med partneren Seagen med lægemidlet Tikdav nået de primære endemål i et fase 3-studie af andenlinje-behandling af patienter med tilbagevendende eller metastatisk livmoderhalskræft. | Photo: Medwatch
af marketwire

Genmab and Seagen have met primary endpoints in a Phase III study of second-line treatment with the drug Tivdak (tisotumab vedotin-tftv) in patients with recurrent or metastatic cervical cancer.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading